The authors describe a study in which “bipolar families,” compared with families without a serious mental illness, incurred much higher medical costs, visited physicians more often, had more hospital stays, and spent more money on prescription drugs.
You are here
P&T® Journal contents for January 2008
Second-generation atypical antipsychotic drugs carry a lower risk of extrapyramidal symptoms and tardive dyskinesia compared with conventional agents, but they are not without their dangers. The case report of a 46-year-old patient demonstrates the point that the newer agents should be used according to their FDA-approved indications, when possible, and that patients using aripiprazole, an “atypical atypical” agent, need to be carefully monitored.
Although the “vaccine revolution” has resulted in products that can prevent illness and reduce costs of disease, the authors raise several concerns: who will pay for these improvements, how these advances will alter treatment, how cost and efficacy will be balanced, and how to choose the right product.
Presentations cover a number of clinical trials of cardiac agents, including clopidogrel versus prasugrel; an investigative thrombin receptor antagonist; a niacin/simvastatin combination; warfarin dosing versus genotype-guided dosing; clopidogrel eptifibatide, and bivalirudin; and eptifibatide versus abciximab.
Topics include nilotinib (Tasigna Capsules) for the treatment of chronic myelogenous leukemia (CML), raltegravir (Isentress) for patients with HIV-1 infection, and ixabepilone (Ixempra), combined with capecitabine (Xeloda), for use in metastatic or locally advanced breast cancer.